Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS

Neurology

Volumn 53, Issue 8, 1999, Pages 1698-1704

  Rudick, R A ^a   Fisher, E ^a   Lee, J C ^a   Simon, J ^b   Jacobs, L ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c BUFFALO GENERAL HOSPITAL   (United States)

Author keywords

Brain atrophy; Interferon beta; MRI; MS

Indexed keywords

BETA1A INTERFERON;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN CORTEX; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARENCHYMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION;

EID: 0033544320     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.8.1698     Document Type: Article

References (22)

1. Simon JH. Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis. J Magn Reson Imaging 1997;7:29-37.
2. McFarland HF, Stone LA, Calabresi PA, Maloni H, Bash CN, Frank JA. MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapies. Mult Scler 1996;2:198-205.
3. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-766.
4. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994; 44:635-641.
5. Arnold DL, Riess GT, Matthews PM, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994;36:76-82.
6. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
7. Simon JH, Jacobs LD, Campion M, et al. A longitudinal study of brain atrophy in relapsing MS. Neurology 1999;53:139-148.
8. The IFNB Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
9. Paty DW, Li DK, UBC MS/MRI Study Group, The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
10. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
11. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
12. Jacobs L, Cookfair DL, Rudick RA, et al. A phase III trial of intramuscular recombinant beta interferon as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Mult Scler 1995;1:118-135.
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
14. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998;43:79-87.
15. Fisher E, Cothren RM, Tkach JA, Masaryk TJ, Cornhill JF. Knowledge-based 3D segmentation of MR images for quantitative MS lesion tracking. SPIE Med Imag 1997;3034:599-610.
16. Filippi M, Colombo B, Rovaris M, Pereira C, Martinelli V, Comi G. A longitudinal magnetic resonance imaging study of the cervical cord in multiple sclerosis. J Neuroimaging 1997;7: 78-80.
17. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996;119: 2009-2019.
18. Losseff NA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;119:701-708.
19. Simon JH, Schiffer RB, Rudick RA, Herndon RM. Quantitative determination of MS-induced corpus callosum atrophy in vivo using MR imaging. Am J Neuroradiol 1987;8:599-604.
20. Cover KS, Petkau J, Paty DW. Lesion load reproducibility and statistical sensitivity of clinical trials in multiple sclerosis. Neurology 1999;52:433-434.
21. Trapp BD, Ransohoff RM, Fisher E, Rudick RA. Neurodegeneration in multiple sclerosis: relationship to neurological disability. The Neuroscientist 1999;5:48-57.
22. Cook RD, Wisniewski HM. The role of oligodendroglia and astroglia in Wallerian degeneration of the optic nerve. Brain Res 1973;61:191-206.